Beta-blockers in heart failure patients with severe chronic kidney disease—time for a randomized controlled trial? by Agarwa, Rajiv & Rossignol, Patrick
15. Sedeek M, Nasrallah R, Touyz RM et al. NADPH oxidases, reactive oxygen
species, and the kidney: friend and foe. J Am Soc Nephrol 2013; 24: 1512–1518
16. Yiu WH, Wong DW, Wu HJ et al. Kallistatin protects against diabetic ne-
phropathy in db/db mice by suppressing AGE-RAGE-induced oxidative
stress. Kidney Int 2016; 89: 386–398
17. de Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for reno-
protection in patients with type 2 diabetic nephropathy: lessons from
RENAAL. Kidney Int 2004; 65: 2309–2320
18. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular out-
comes, and mortality in type 2 diabetes.N Engl J Med 2015; 373: 2117–2128
19. Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and progression of
kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323–334
20. Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and renal outcomes in
type 2 diabetes and nephropathy.N Engl J Med 2019; 380: 2295–2306
21. Dekkers CCJ, Wheeler DC, Sjostrom CD et al. Effects of the sodium–
glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 dia-
betes and Stages 3b–4 chronic kidney disease. Nephrol Dial Transplant
2018; 33: 2005-2011
22. Chan GCW, Tang S. SGLT2 inhibitor empagliflozin: finally at the latter
stage of understanding? Kidney Int 2018; 93: 22–24
23. Skov-Jeppesen SM, Yderstraede KB, Bistrup C et al. Low-intensity shock-
wave therapy in the treatment of diabetic nephropathy: a prospective Phase
1 study.Nephrol Dial Transplant 2018; https://doi.org/10.1093/ndt/gfy375
24. d’Agostino MC, Craig K, Tibalt E et al. Shock wave as biological therapeutic
tool: Frommechanical stimulation to recovery and healing, through mecha-
notransduction. Int J Surg 2015; 24(Pt B): 147–153
25. Hatanaka K, Ito K, Shindo T et al. Molecular mechanisms of the angiogenic
effects of low-energy shock wave therapy: roles of mechanotransduction.
Am J Physiol Cell Physiol 2016; 311: C378–C385
26. Burneikaite G, Shkolnik E, Celutkiene J et al. Cardiac shock-wave therapy in
the treatment of coronary artery disease: systematic review and meta-analy-
sis. Cardiovasc Ultrasound 2017; 15: 11
27. Hayashi D, Kawakami K, Ito K et al. Low-energy extracorporeal shock
wave therapy enhances skin wound healing in diabetic mice: a critical role of
endothelial nitric oxide synthase.Wound Repair Regen 2012; 20: 887–895
28. Deferrari G, Bonanni A, Bruschi M et al. Remote ischaemic preconditioning
for renal and cardiac protection in adult patients undergoing cardiac
surgery with cardiopulmonary bypass: systematic review and meta-analysis of
randomized controlled trials.Nephrol Dial Transplant 2018; 33: 813–824
Received: 25.4.2019; Editorial decision: 27.5.2019
Nephrol Dial Transplant (2020) 35: 728–731
doi: 10.1093/ndt/gfz187
Advance Access publication 3 October 2019
Beta-blockers in heart failure patients with severe chronic
kidney disease—time for a randomized controlled trial?
Rajiv Agarwal1 and Patrick Rossignol2
1Department of Medicine, Division of Nephrology, Indiana University School of Medicine, Indianapolis, IN, USA and 2University of Lorraine,
Inserm 1433 CIC-P CHRU de Nancy, Inserm U1116 and FCRIN INI-CRCT, Nancy, France
Correspondence and offprint requests to: Rajiv Agarwal; E-mail: ragarwal@iupui.edu
Cardiovascular disease is a major cause of morbidity and mor-
tality in patients with chronic kidney disease (CKD).
Hospitalizations from heart failure are among the most com-
monly observed cardiovascular morbidity seen in clinical trials
among those with Type 2 diabetes and CKD [1, 2]. The heart
failure guidelines recommend that among patients with heart
failure with reduced ejection fraction (HFrEF), the following
drugs be prescribed to reduce cardiovascular morbidity and
mortality: angiotensin-converting enzyme inhibitors, angioten-
sin receptor blockers, angiotensin receptor–neprilysin inhibitor,
evidence-based b-blockers and mineralocorticoid receptor
antagonists in selected patients [3, 4]. However, the evidence
base for this is essentially nonexistent for those with Stage 4
CKD. In part, this is because patients with advanced CKD are
almost systematically excluded from trials of heart failure [5, 6].
Thus, to guide therapy in this high-risk population, we are lim-
ited to small subgroup analyses of randomized clinical trials or
to observational data [7].
In this issue of Nephrology Dialysis Transplantation, Molnar
et al. [8] report a retrospective observational study examining
the modifying effect of levels of CKD determined by estimated
glomerular filtration rate (eGFR) on the cardiovascular protec-
tion afforded by b-blockers. Cardiovascular protection of
b-blockers was assessed by examining the relationship between
incident congestive heart failure (CHF) and subsequent all-
cause mortality among patients aged 66 years. In Ontario,
Canada, they identified 320 703 such patients who had incident
CHF; only 27 777 (8.7%) were not receiving b-blockers. Of
these, 5862 (21.1%) started on a b-blocker soon after hospitali-
zation. These patients were matched on age (62 years), sex,
CKD stage and CHF diagnosis date (62 years) to nonusers of
b-blockers. Because patients who may be treated were not se-
lected at random from the total pool of patients, a high-dimen-
sional propensity score (HDPS) was used to match users and
nonusers (within 0.2 SD of the logit score of HDPS). This
reduces bias of b-blocker prescription at least to the extent con-
trolled by factors specified in HDPS. Although the motivation
was to draw causal inference from the analysis, this should be
strongly cautioned against as with the use of such a technique,
unmeasured biases that could be at least as large as the apparent
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association with b-blocker and subsequent outcomes cannot be
excluded.
In the nonusers group, over a median follow-up of
0.61 years, 1424 (24%) patients died yielding an incident mor-
tality rate of 169.6/1000 patient-years. In contrast, in the b-
blocker group, over a median follow-up of 0.72 years, 937
(16%) patients died yielding an incident mortality rate of 103.5/
1000 patient-years. The incidence rate ratio was 0.61 [95% con-
fidence interval (CI) 0.56–0.66]. In a time-to-event analysis
(Cox proportional hazards model), the hazard ratio (HR) was
0.58 (95% CI 0.54–0.64). Thus, the two analyses were concor-
dant (see Figure 1).
The central question posed in this study was whether the
CKD stage modified the relationship between b-blocker use
and all-cause mortality. To test this hypothesis, the authors clas-
sified the patients as CKD Stages 3 and 4; CKD Stages 1 and 2
served as comparator. The HR for all-cause mortality in CKD
Stage 1 or 2 was 0.55, Stage 3 was 0.63 and Stage 4 was 0.55. The
interaction effect was not significant (P¼ 0.3), which means
that the severity of CKD did not modify the relationship be-
tween b-blocker use and all-cause mortality in patients with in-
cident CHF. In the above analysis, the authors censored
patients in the nonuser group when b-blocker was started.
They also censored patients in the b-blocker group when the
drugs were stopped. This is akin to a ‘per-protocol’ analysis in a
randomized controlled trial. In a sensitivity analysis, they re-
laxed the assumption, making it analogous to an intention-to-
treat analysis. In the intention-to-treat analysis, the severity of
CKD still did not modify the relationship between b-blocker
use and all-cause mortality. However, the HR increased from
0.58 to 0.64. In other words, the apparent protection afforded
by beta-blocker use was less.
The authors provide even more evidence for the protective
effect of b-blocker use in elderly patients with CHF that
emerged from a time-varying analysis of b-blocker use. The HR
in the time-varying analysis was 0.44 (95% CI 0.40–0.48). The
upper bound of the time-varying HR was lower than the lower
bound of the primary analysis. Taken together, this suggests
that b-blocker use is associated with reduced all-cause mortality
in CHF. This observation is well supported by clinical trials in
patients without advanced CKD. More importantly, this study
shows that the CKD stage does not modify the protective rela-
tionship between b-blockers use in incident CHF and all-cause
mortality. Furthermore, this protection extends to Stage 4
CKD.
Overall, we can calculate from the data provided by the
authors that only 17.3 elderly patients with CHF need to be
treated for 1 year to prevent one death [9]. However, just 10.3
elderly patients with CHF and CKD Stage 4 need to be treated
for 1 year to prevent one death. Although recurrent hospitaliza-
tion from heart failure was not reported, it is quite likely that
health-related quality of life, morbidity and costs are also likely
to benefit in those with advanced CKD even more so than in
those with earlier stages of CKD.
Some limitations of the analyses should be pointed out. First,
although the motivation of HDPS matching was to draw causal
inference from the analysis, even with the use of such a tech-
nique, the unmeasured biases are not eliminated. Second,
whether b-blocker should be used on top of renin–angiotensin–
aldosterone system (RAAS) inhibitors is unclear from this re-
port. The P-value for interaction was 0.07, suggesting that renal
failure may modify the relationship between b-blocker and
mortality when RAAS inhibitor is not used. Third, mineralo-
corticoid receptor antagonists are used minimally in those with
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FIGURE 1: Level of CKD as determined by the eGFR does not affect the protective effect of b-blocker in incident heart failure as judged by all-
cause mortality. The incidence rate (IR) per 1000 patient-years is higher in those with severe CKD, but the mortality benefit is similar to those
with less severe degrees of CKD (top three rows). The absolute risk of all-cause mortality was greater in those with severe CKD. Accordingly,
the number needed to treat was lower. The time-to-event analyses were similar to the event rate analyses. IRR, incidence rate ratio.
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CKD, likely because of their propensity to cause hyperkalemia.
Whether their use should be mandated prior to b-blocker use
in CKD similarly remains unknown. Fourth, the lack of ejection
fraction data, as acknowledged by the authors themselves,
which prevented them from determining if the ‘observed sur-
vival benefit extends to all elderly patients with CHF and CKD
or only those with CHF and HFrEF’. Indeed, b-blockers are
evidence-based live-saving drugs in HFrEF only, whereas in
heart failure with preserved ejection fraction, none of the treat-
ments tested to date has been definitively proven to improve
survival [3, 4]. Fifth, the study likely magnified the mortality
benefit of b-blocker use. For example, in a Lancetmeta-analysis,
b-blocker use among patients participating in randomized trials
and who were in sinus rhythm had an HR for all-cause mortal-
ity of 0.73 (95% CI 0.67–0.80) [10]. This is much smaller than
the analysis reported by Molnar et al. [HR 0.58 (95% CI 0.54–
0.64)]. Sixth, the presence of atrial fibrillation modifies the pro-
tective effect of b-blocker in patients with HFpEF in which it
has no protective effect on all-cause mortality [10]. Although
Molnar et al. adjusted for the presence or absence of atrial fibril-
lation, the interaction effect was not reported.
In this study, the severity of CKD did not modify the CHF–
mortality relationship even with those b-blockers that have not
had the evidence base of cardiovascular protection in clinical
trials among patients with CHF. Such b-blockers include meto-
prolol tartrate and atenolol. In other words, even the ‘non-evi-
dence-based b-blockers’ afforded all-cause mortality protection
in patients with incident CHF. Only 6% of the study population
was on atenolol in this study, but among dialysis patients—not
a subject of study in this report—atenolol administered three
times a week protects from both hard cardiovascular outcomes
and hospitalization from heart failure [11]. This therapy is inex-
pensive and in the USA, an annual supply of atenolol adminis-
tered 50mg once daily costs just $20. This drug is not
metabolized and is removed by the kidney, and therefore in
patients with CKD can be used just once a day and in those on
dialysis three times weekly after dialysis. Thus, the benefit of b-
blockers may extend to patients on long-term dialysis.
Cardiovascular trialists should take note of these data. From
this well-done pharmacoepidemiology study, it is evident that
inclusion of patients with Stage 4 CKD may reduce the size of
the trials owing to the much higher event rate and provide ben-
efit similar to that seen among those without CKD. Despite its
size, observational studies are subject to various biases and con-
founding and should not be taken as evidence of cause and ef-
fect [12]. Whether b-blockers can save lives, alleviate
hospitalizations for heart failure and reduce costs appears
promising, but whether it is so will require adequately powered
and specifically designed randomized trials. Indeed, the limita-
tions of standard endpoint definitions in patients with CKD are
well known: they encompass difficulties in determining whether
some signs and symptoms commonly used to identify an end-
point event (e.g. heart failure) are attributable to cardiovascular
disease or to the underlying kidney disease. Furthermore, some
biomarkers (e.g. natriuretic peptides) may be altered in CKD
and interpretation can be challenging [13]. Another hurdle may
be the potential reluctance of the medical community in some
countries to acknowledge the equipoise and challenge some
established medical practices despite a poor evidence base. As
an example, Bosselmann et al. [14] identified patients with sys-
tolic heart failure in the Danish Heart Failure database and
new-onset end-stage renal disease. In this setting, despite a poor
evidence base, 82% of the patients with a baseline Stage 4 CKD
were treated with a b-blocker. Thus, there may be reluctance on
part of physicians to test the b-blocker hypothesis in a random-
ized controlled trial among patients with Stage 4 CKD. If so, we
will continue to practice despite a poor evidence base.
In our view, however, it is time to perform such a study—the
costs of doing nothing are too high.
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Twenty-five years after the publication of the seminal
Modification of Diet in Renal Disease (MDRD) Study, which
suggested a small benefit of dietary protein restriction on the
progression of chronic kidney disease (CKD) [1], there are con-
siderable variations from one centre to another, even from one
nephrologist to another, in the prescription of protein restric-
tion for various matters. These are linked to scientific andmedi-
cal considerations, but also to feasibility, acceptance by patients
and the organization of health care. In this context, sharing of
expertise by centres that have long-term experience with pro-
tein restriction might be useful to share, even in the perspective
of reassessment of the effect of protein restriction in CKD in a
properly designed randomized clinical trial (RCT) [2]. In this
issue of Nephrology Dialysis Transplantation, Piccoli et al. [3]
report the experience of the use of protein restriction in 422
patients with CKD Stages 1–5D in four centres in Italy. The
study is focused on quality of life (QoL) and dietary satisfaction
of these patients, i.e. objectives different from most studies
that have evaluated the impact of protein restriction on CKD
progression and other clinical endpoints, including end-stage
kidney disease (ESKD).
As a matter of fact, the debate over the effectiveness of pro-
tein restriction is far from closed; in a recent Cochrane review,
Palmer et al. [2] stated that ‘dietary interventions may prevent
one person in every 3000 treated for one year avoiding ESKD,
although the certainty in this effect was very low’. Nevertheless,
there were significant beneficial effects of protein restriction on
systolic and diastolic blood pressure, estimated glomerular fil-
tration rate (eGFR) and low-density lipoprotein cholesterol. In
an even more recent Cochrane review, it was found that very
low protein intake compared with a low protein intake probably
reduces the number of patients who reach ESKD (165 per 1000
fewer reached ESKD), but the evidence was of moderate cer-
tainty [4]. Both reviews conclude that large-scale pragmatic
RCTs are needed to test the effects of dietary interventions
on patient outcomes [2, 4]. This study contains important
information to be taken into account if such RCTs are to be
performed, given the experience of our Italian colleagues, with
the present cohort being one of the largest reported so far.
The first information is that protein restriction may not be
proposed to all patients with CKD, since it is not adapted
to patients with high comorbidities, malnutrition or poor life
expectancy and since patients may not want to limit their
protein intake [3]. This latter aspect may depend on cultural
background and habits. Global protein intake is two times
higher in industrialized countries, with meat intake being three
times higher. In consumers of Mediterranean diets, such as in
Italy, an equilibrium exists between plant and animal protein,
and it is easier to reduce protein intake than in meat eaters [5].
Protein restriction is therefore a relative concept [6], depending
on regional and personal dietary protein consumption. In this
respect, the authors are right to highlight the Mediterranean
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